---
title: "Key facts: Johnson & Johnson announces 2.1% dividend; reports Tremfya data"
description: "Johnson & Johnson (JNJ) announced a dividend yield of 2.1%, with a dividend amount of $1.30, as part of the stocks ex-dividend list dated February 24.1Johnson & Johnson reported long-term data for Tre"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/276519560.md"
published_at: "2026-02-21T20:03:10.000Z"
---

# Key facts: Johnson & Johnson announces 2.1% dividend; reports Tremfya data

> Johnson & Johnson (JNJ) announced a dividend yield of 2.1%, with a dividend amount of $1.30, as part of the stocks ex-dividend list dated February 24.1Johnson & Johnson reported long-term data for Tremfya (guselkumab), showing sustained clinical and endoscopic remission in ulcerative colitis patients over a three-year period.2

-   Johnson & Johnson (JNJ) announced a dividend yield of 2.1%, with a dividend amount of $1.30, as part of the stocks ex-dividend list dated February 24.1
-   Johnson & Johnson reported long-term data for Tremfya (guselkumab), showing sustained clinical and endoscopic remission in ulcerative colitis patients over a three-year period.2

### Related Stocks

- [IHE.US - iShares US Pharma](https://longbridge.com/en/quote/IHE.US.md)
- [XLV.US - Health Care Select Sector SPDR](https://longbridge.com/en/quote/XLV.US.md)
- [IXJ.US - iShares Global Healthcare](https://longbridge.com/en/quote/IXJ.US.md)
- [JNJ.US - Johnson & Johnson](https://longbridge.com/en/quote/JNJ.US.md)
- [VHT.US - VG Health](https://longbridge.com/en/quote/VHT.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 强生｜10-K：2025 财年营收 942 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/275658131.md) |
| Uniting Wealth Partners LLC 收购了 5,056 股强生公司$JNJ 股票 | 联合财富伙伴公司（Uniting Wealth Partners LLC）在第三季度收购了 5,056 股强生（Johnson & Johnson，NYSE: JNJ），价值约为 938,000 美元。其他机构投资者也调整了他们的持仓，SO | [Link](https://longbridge.com/en/news/276006840.md) |
| TREMFYA®（guselkumab）长期数据表明在溃疡性结肠炎中，经过 3 年的治疗，患者持续达到临床和内镜缓解 \| 强生股票新闻 | 强生公司宣布了 QUASAR 研究的长期数据，显示 TREMFYA®（guselkumab）在 140 周内能够维持溃疡性结肠炎患者的临床和内镜缓解。超过 80% 的参与者处于临床缓解状态，53.6% 达到了内镜缓解。该研究证明了无论之前的 | [Link](https://longbridge.com/en/news/276513760.md) |
| FDA 发出无标题信，批评强生 Tremfya 广告中的声明 | 美国食品药品监督管理局（FDA）已向强生公司发出了一封无标题信函，涉及其在 Tremfya（用于溃疡性结肠炎的药物）广告中存在的误导性声明。信函批评了关于该药物疗效的声明，指出广告中声称 “许多人” 能够实现临床缓解的说法具有误导性，因为该 | [Link](https://longbridge.com/en/news/276359346.md) |
| 强生公司因计划在宾夕法尼亚州进行 10 亿美元投资而股价上涨 | 强生（Johnson & Johnson，JNJ）的股价上涨 0.3%，至 244.40 美元，此次上涨是由于公司宣布计划投资超过 10 亿美元在宾夕法尼亚州建立一个新的细胞治疗设施。这项投资是为了应对关税威胁而制定的更广泛战略的一部分，旨 | [Link](https://longbridge.com/en/news/276261089.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.